De Los Ríos Tatiana, Pérez-Martínez Juan, Portoles Jose, Lichodziejewska-Niemierko Monika, Rivera Maite, Nowicki Michał, Książek Andrzej, Tato Ana María, Bohnhorst Christine, Feriani Mariano
Clinical Research, Fresenius Medical Care Deutschland GmbH, Bad Homburg, Germany
Nephrology, University Hospital of Albacete, Albacete, Spain.
Perit Dial Int. 2016;36(5):569-72. doi: 10.3747/pdi.2015.00010.
Interference of conventional peritoneal dialysis fluids (cPDFs) with peritoneal membrane cell functions may be attributed to the dialysis fluid's low pH, high glucose concentration, and/or the presence of glucose degradation products (GDPs), the last of which leads to higher levels of advanced glycation end-products (AGEs). It has been suggested that the peritoneal membrane might be better preserved by using biocompatible solutions, including cancer antigetn 125 (CA125). This prospective, open-label, multicentre, randomized, controlled, cross-over phase IV study compared the in vivo biocompatibility of a neutral-pH, low-GDP peritoneal dialysis (PD) solution (balance) with a cPDF in automated PD (APD) patients. Our study revealed a significantly increased appearance rate and concentration of CA125 in the peritoneal effluent of APD patients treated with the neutral-pH, low-GDP solution balance versus a conventional PD solution.
传统腹膜透析液（cPDFs）对腹膜细胞功能的干扰可能归因于透析液的低pH值、高葡萄糖浓度和/或葡萄糖降解产物（GDPs）的存在，其中最后一项会导致晚期糖基化终产物（AGEs）水平升高。有人提出，使用生物相容性溶液，包括癌抗原125（CA125），可能会更好地保护腹膜。这项前瞻性、开放标签、多中心、随机、对照、交叉IV期研究比较了中性pH、低GDP腹膜透析（PD）溶液（平衡液）与cPDF在自动化腹膜透析（APD）患者体内的生物相容性。我们的研究显示，与传统腹膜透析液相比，使用中性pH、低GDP溶液平衡液治疗的APD患者腹膜流出液中CA125的出现率和浓度显著增加。
Zotero 插件